Similar articles

• Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.

  Herr HW. Herr HW. J Urol. 2005 Dec;174(6):2134-7. doi: 10.1097/01.ju.0000181799.81119.fc. J Urol. 2005. PMID: 16280743
• Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.

  Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Lerner SP, et al. J Urol. 2007 May;177(5):1727-31. doi: 10.1016/j.juro.2007.01.031. J Urol. 2007. PMID: 17437798 Clinical Trial.
• Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer.

  Hinotsu S, Akaza H, Naito S, Ozono S, Sumiyoshi Y, Noguchi S, Yamaguchi A, Nagamori S, Terai A, Nasu Y, Kume H, Tomita Y, Tanaka Y, Samma S, Uemura H, Koga H, Tsushima T. Hinotsu S, et al. BJU Int. 2011 Jul;108(2):187-95. doi: 10.1111/j.1464-410X.2010.09891.x. Epub 2010 Dec 22. BJU Int. 2011. PMID: 21176079 Clinical Trial.
• Management of BCG failures in superficial bladder cancer: a review.

  Witjes JA. Witjes JA. Eur Urol. 2006 May;49(5):790-7. doi: 10.1016/j.eururo.2006.01.017. Epub 2006 Jan 24. Eur Urol. 2006. PMID: 16464532 Review.
• [Bacillus of Calmette-Guérin immunotherapy: which protocol?].

  Saint F. Saint F. Prog Urol. 2008 May;18 Suppl 5:S99-104. doi: 10.1016/S1166-7087(08)72485-0. Prog Urol. 2008. PMID: 18585635 Review. French.